Tempus AI (NASDAQ:TEM) Price Target Cut to $60.00 by Analysts at Guggenheim

Tempus AI (NASDAQ:TEM) had its target price cut by Guggenheim from $95.00 to $60.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also recently issued reports on TEM. Mizuho started coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price for the company. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. JPMorgan Chase & Co. lowered their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, Robert W. Baird started coverage on shares of Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.92.

Tempus AI Trading Down 0.6%

NASDAQ TEM opened at $42.37 on Monday. The firm has a market cap of $7.57 billion, a P/E ratio of -30.05 and a beta of 5.29. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The stock’s 50-day moving average is $54.55 and its 200-day moving average is $69.26. Tempus AI has a one year low of $36.22 and a one year high of $104.32.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at $41,001,603.70. The trade was a 1.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Ryan M. Bartolucci sold 2,902 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $171,363.10. Following the transaction, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. This represents a 6.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 568,841 shares of company stock worth $32,579,611. 26.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Cranbrook Wealth Management LLC bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $25,000. JPL Wealth Management LLC bought a new position in shares of Tempus AI in the third quarter valued at $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI during the fourth quarter worth $27,000. GAMMA Investing LLC acquired a new position in Tempus AI during the third quarter worth $28,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Tempus AI during the third quarter worth $38,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.